17 September, 2026
In a landmark decision that promises to reshape the landscape of public health policy across the European Union, Members of the European Parliament (MEPs) have officially voted to adopt the Public Health Committee’s comprehensive report on cardiovascular diseases (CVD). This legislative milestone represents more than a policy update; it is a decisive pivot toward a holistic, integrated framework for tackling non-communicable diseases (NCDs), prioritizing prevention, early diagnosis, and the recognition of complex comorbidities.
The adoption of this report, a direct response to the European Commission’s ambitious "Safe Hearts Plan," signals an end to the era of siloed healthcare. By formally acknowledging the intrinsic, physiological links between cardiovascular health and respiratory function, the Parliament has set the stage for a new generation of health interventions that aim to reduce the staggering burden of chronic illness on European citizens and healthcare systems alike.
The Core Mandate: Why the "Safe Hearts Plan" Matters
The European Commission’s "Safe Hearts Plan" was drafted as a strategic response to the rising prevalence of heart disease, which remains a leading cause of mortality in Europe. However, the Parliament’s report goes a step further by emphasizing that cardiovascular health cannot be viewed in isolation.
At the heart of the new policy is the understanding that patients rarely suffer from one condition in a vacuum. The report highlights the high prevalence of comorbidities—specifically the frequent co-existence of cardiovascular issues with chronic obstructive pulmonary disease (COPD) and obstructive sleep apnoea. By integrating respiratory health into the broader cardiovascular narrative, the EU is moving toward a “cross-disease” approach to medicine that promises to streamline patient pathways and improve long-term outcomes.
Chronology of the Legislative Journey
The road to the 17 September vote was marked by extensive consultation, scientific advocacy, and a shifting understanding of European health data.
- Early 2025: The European Commission introduces the Safe Hearts Plan, setting out a vision for reducing cardiovascular mortality through digital health integration and improved screening protocols.
- Q3 2025: The European Parliament’s Committee on Public Health begins hearings. Stakeholders, including the European Respiratory Society (ERS), are invited to present evidence on the intersection of heart and lung health.
- Q1 2026: Drafting of the Committee report begins. Advocacy groups emphasize the need for "integrated care," pushing for the inclusion of respiratory assessments in standard cardiovascular screening.
- June 2026: The report undergoes rigorous committee review. Amendments are introduced to ensure that socioeconomic inequalities in health are addressed, acknowledging that marginalized populations face higher risks of both CVD and respiratory distress.
- 17 September 2026: The European Parliament votes to adopt the report, cementing it as the guiding framework for EU-wide cardiovascular health initiatives.
Supporting Data: The Case for Integration
The shift toward integrated care is not merely a political preference; it is a data-driven necessity. Cardiovascular and respiratory systems share common risk factors, including environmental exposure (such as air pollution), smoking, and physical inactivity.
The Comorbidity Crisis
Data presented during the parliamentary hearings underscored the severity of the challenge:
- Synergistic Risk: Patients with COPD are significantly more likely to develop ischemic heart disease, heart failure, and arrhythmias. The inflammatory nature of lung conditions often exacerbates systemic cardiovascular stress.
- Sleep Apnoea and Heart Health: Obstructive sleep apnoea is now recognized as an independent risk factor for hypertension and stroke. Despite this, millions of cases remain undiagnosed across the EU.
- The Cost of Inaction: NCDs account for nearly 80% of healthcare spending in Europe. By failing to detect respiratory issues early, health systems are often left treating advanced, expensive-to-manage heart failure cases that could have been mitigated through proactive pulmonary screening.
The European Respiratory Society (ERS) has been at the forefront of this data-driven advocacy. Through initiatives like "EU Screening Week," the society has urged policymakers to include lung function testing in standardized health checks. Their argument is compelling: if a patient is already undergoing cardiovascular screening, a simple, non-invasive spirometry test could catch early-stage respiratory disease, drastically improving life expectancy and quality of life.
Official Responses and Strategic Vision
The adoption of the report has been met with widespread approval from the scientific and medical communities. The emphasis on "prevention first" aligns with the shifting priorities of modern medicine.
Raquel Duarte, the ERS Director of Scientific Affairs to the EU, issued a formal statement following the vote, highlighting the gravity of the decision:
"This vote by the European Parliament marks an important step towards strengthening cardiovascular and respiratory health together. The Safe Hearts Plan provides a valuable framework for addressing cardiovascular disease, and importantly its comorbidities and precursors across the entire health pathway—from prevention and early detection to treatment and rehabilitation."
Duarte’s comments underline a crucial point: the policy is not just about the moment of diagnosis, but the entire lifecycle of the patient. She added:
"We particularly welcome the strong focus on prevention, COPD, and on addressing the risk factors and inequalities that continue to shape cardiovascular health outcomes across Europe. The next step now is to ensure that the Safe Hearts Plan translates into clear and effective measures across the EU with the cooperation between European institutions, Member States, the scientific community, healthcare professionals, patients, and civil society."
Implications: From Policy to Patient Care
The long-term implications of this vote will be felt in hospitals, primary care clinics, and research laboratories across the EU.
1. Unified Screening Pathways
Member states are now expected to harmonize their screening protocols. We can anticipate the rollout of integrated “heart-lung” health assessments in national screening programs. For the patient, this means fewer appointments, more comprehensive diagnostics, and a clearer picture of their overall health profile.
2. Addressing Health Inequalities
The report explicitly calls for a reduction in the health disparities that plague different regions of Europe. By targeting environmental factors—such as air quality—and investing in preventative care in underserved communities, the EU aims to level the playing field. This is an essential step, as current data shows that mortality rates for NCDs are disproportionately higher in lower-income demographics.
3. Fostering Multidisciplinary Collaboration
The "cross-disease" approach necessitates a move away from rigid medical specialties. Cardiologists, pulmonologists, and general practitioners will need to work in tandem. This will likely drive demand for new digital health platforms that allow for the seamless sharing of patient data across departments, ensuring that a patient’s heart health is always visible to their respiratory specialist, and vice versa.
4. A Template for Future Policy
This report may serve as a template for other areas of medicine. If the integration of cardiovascular and respiratory health proves successful, it could pave the way for similar integrated approaches to cancer, diabetes, and mental health, further cementing the EU’s role as a global leader in evidence-based public health reform.
Conclusion: A New Horizon for European Health
The 17 September vote is a watershed moment. By acknowledging the complex, intertwined nature of the human body, the European Parliament has moved away from the outdated model of fragmented care. The implementation of the Safe Hearts Plan will require years of diligent effort, cross-border cooperation, and significant investment in public health infrastructure.
However, the vision is clear: a Europe where chronic diseases are detected early, managed holistically, and addressed with the urgency they deserve. As the EU institutions begin the work of translating this report into actionable legislation, the medical community remains hopeful. If the promises of this report are fulfilled, the primary beneficiaries will be the millions of Europeans whose health—and future—depend on a more integrated, proactive, and compassionate approach to medicine.
For more information on the ongoing advocacy regarding these policies, readers are encouraged to consult the European Respiratory Society and European Lung Foundation policy portal.
